Jazz Pharmaceuticals's quarterly market cap
increased
from Sep. 2025 (€0 Mil) to Dec. 2025 (€8,887 Mil) and
increased
from Dec. 2025 (€8,887 Mil) to Mar. 2026 (€10,085 Mil).
Jazz Pharmaceuticals's annual market cap
stayed the same
from Dec. 2023 (€0 Mil) to Dec. 2024 (€0 Mil) but then
increased
from Dec. 2024 (€0 Mil) to Dec. 2025 (€8,887 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Jazz Pharmaceuticals's Enterprise Value for Today is €15,530 Mil.
Jazz Pharmaceuticals (HAM:J7Z) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Jazz Pharmaceuticals Market Cap Related Terms
Jazz Pharmaceuticals Market Cap Historical Data
* Premium members only.
The historical data trend for Jazz Pharmaceuticals's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:J7Z vs BBIO, EXEL, IONS: Market Cap Comparison
For the Biotechnology subindustry, Jazz Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jazz Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Jazz Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals (HAM:J7Z) has a Market Cap of €13,298 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Jazz Pharmaceuticals and its competitors. According to the industry distribution chart, Jazz Pharmaceuticals ranks #21 out of 1428 companies in the Biotechnology industry, placing it in the top 1.5%.
Is Jazz Pharmaceuticals' Market Cap too high?
Jazz Pharmaceuticals' current Market Cap is €13,298 Mil. Based on the distribution chart, Jazz Pharmaceuticals ranks #21 out of 1428 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Market Cap compare to BBIO and EXEL?
According to the Biotechnology industry distribution chart, Jazz Pharmaceuticals ranks #21 out of 1428 companies for Market Cap. This places Jazz Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median Market Cap is 119.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.44, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Jazz Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 119.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jazz Pharmaceuticals's current Market Cap is €13,298 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (HAM:J7Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €127.01, compared to a current price of €209.50 — trading 64.9% above its estimated fair value. The current Market Cap is €13,298 Mil. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Jazz Pharmaceuticals (HAM:J7Z), the current Market Cap is €13,298 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jazz Pharmaceuticals (HAM:J7Z) Overvalued in 2026?
Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued.
The current stock price of €209.50 is trading 64.9% above its estimated GF Value™ of €127.01.
GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for HAM:J7Z:
Market Cap: €13,298 Mil
GF Value™: €127.01 vs. price of €209.50 (64.9% above fair value)
No single metric tells the full story. See the HAM:J7Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score
Get the complete analysis for HAM:J7Z
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:J7Z has been successfully added to your 
